神经丝轻链升高与多发性硬化残疾进展
该研究纳入两个观察性队列(EPIC和SMSC),分析血清神经丝轻链(NfL)z分数与确认的残疾恶化(CDW)的关系。结果显示,在临床复发相关CDW(CDW-R)前一次访视时NfL z分数已升高,而在非复发相关CDW(CDW-NR)前两次访视即可检测到升高。时间事件分析证实NfL水平与未来约1年内CDW-R及约1-2年内CDW-NR相关。
要点
- 在CDW-R事件前一次访视,NfL z分数较稳定MS样本升高:EPIC队列高0.71(95%CI 0.35-1.07),SMSC队列高0.32(95%CI 0.14-0.49)。
- 在CDW-NR事件前两次访视即可检测到NfL升高:EPIC高0.23(95%CI 0.01-0.45),SMSC高0.28(95%CI 0.18-0.37)。
- 时间事件分析证实NfL水平与未来约1年内CDW-R及约1-2年内CDW-NR相关。
核心结论
- 本队列研究记录到NfL升高出现在临床恶化之前,可能提示在CDW诊断前存在一个持续动态中枢神经系统病理过程的潜在窗口。
研究设计与样本
- 研究纳入两个观察性队列:加州大学旧金山分校的EPIC研究(自2004年起)和瑞士多发性硬化队列(SMSC,自2012年起,8个中心的多中心研究)。
- EPIC队列数据提取于2022年4月(采样时间2004年7月1日至2016年12月20日),SMSC数据提取于2022年12月(采样时间2012年6月6日至2021年9月2日)。
- 纳入两个队列所有有NfL结果的参与者,无合格参与者被排除或拒绝参与。
- 共纳入3906次EPIC访视(609名参与者;中位[IQR]年龄42.0[35.0-50.0]岁;424名女性[69.6%])和8901次SMSC访视(1290名参与者;中位[IQR]年龄41.2[32.5-49.9]岁;850名女性[65.9%])。
- CDW定义为EDSS恶化且在6个月或更长时间后确认,分为临床复发相关CDW(CDW-R)和独立于临床复发的CDW(CDW-NR)。
主要发现
- 在CDW-R(EPIC 36例事件;SMSC 93例事件)中,与稳定MS样本相比,NfL z分数在CDW-R(-1)时EPIC高0.71单位(95%CI 0.35-1.07;P < .001),SMSC高0.32单位(95%CI 0.14-0.49;P < .001)。
- 在CDW-NR(EPIC 191例事件;SMSC 342例事件)前,NfL升高可在CDW-NR(-2)时检测到(EPIC:0.23;95%CI 0.01-0.45;P = .04;SMSC:0.28;95%CI 0.18-0.37;P < .001),并在CDW-NR(-1)时检测到(EPIC:0.27;95%CI 0.11-0.44;P < .001;SMSC:0.09;95%CI 0-0.18;P = .06)。
- 这些发现在复发缓解型MS亚组中得到重复。
- 时间事件分析证实NfL水平与未来约1年内CDW-R及约1-2年内CDW-NR相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mechanisms contributing to disability accumulation in multiple sclerosis (MS) are poorly understood. Blood neurofilament light chain (NfL) level, a marker of neuroaxonal injury, correlates robustly with disease activity in people with MS (MS); however, data on the association between NfL level and disability accumulation have been conflicting. OBJECTIVE: To determine whether and when NfL levels are elevated in the context of confirmed disability worsening (CDW). DESIGN, SETTING, AND PARTICIPANTS: This study included 2 observational cohorts: results from the Expression, Proteomics, Imaging, Clinical (EPIC) study at the University of California San Francisco (since 2004) were confirmed in the Swiss Multiple Sclerosis Cohort (SMSC), a multicenter study in 8 centers since 2012. Data were extracted from EPIC in April 2022 (sampling July 1, 2004, to December 20, 2016) and SMSC in December 2022 (sampling June 6, 2012, to September 2, 2021). The study included 2 observational cohorts in tertiary MS centers. All participants of both cohorts with available NfL results were included in the study, and no eligible participants were excluded or declined to participate. EXPOSURE: Association between NfL z scores and CDW. MAIN OUTCOME MEASURES: CDW was defined as Expanded Disability Status Scale (EDSS) worsening that was confirmed after 6 or more months and classified into CDW associated with clinical relapses (CDW-R) or independent of clinical relapses (CDW-NR). Visits were classified in relation to the disability worsening events into CDW(-2) for 2 visits preceding event, CDW(-1) for directly preceding event, CDW(event) for first diagnosis of EDSS increase, and the confirmation visit. Mixed linear and Cox regression models were used to evaluate NfL dynamics and to assess the association of NfL with future CDW, respectively. RESULTS: A total of 3906 EPIC visits (609 participants; median [IQR] age, 42.0 [35.0-50.0] years; 424 female [69.6%]) and 8901 SMSC visits (1290 participants; median [IQR] age, 41.2 [32.5-49.9] years; 850 female [65.9%]) were included. In CDW-R (EPIC, 36 events; SMSC, 93 events), NfL z scores were 0.71 (95% CI, 0.35-1.07; P < .001) units higher at CDW-R(-1) in EPIC and 0.32 (95% CI, 0.14-0.49; P < .001) in SMSC compared with stable MS samples. NfL elevation could be detected preceding CDW-NR (EPIC, 191 events; SMSC, 342 events) at CDW-NR(-2) (EPIC: 0.23; 95% CI, 0.01-0.45; P = .04; SMSC: 0.28; 95% CI, 0.18-0.37; P < .001) and at CDW-NR(-1) (EPIC: 0.27; 95% CI, 0.11-0.44; P < .001; SMSC: 0.09; 95% CI, 0-0.18; P = .06). Those findings were replicated in the subgroup with relapsing-remitting MS. Time-to-event analysis confirmed the association between NfL levels and future CDW-R within approximately 1 year and CDW-NR (in approximately 1-2 years). CONCLUSIONS AND RELEVANCE: This cohort study documents the occurrence of NfL elevation in advance of clinical worsening and may hint to a potential window of ongoing dynamic central nervous system pathology that precedes the diagnosis of CDW.
引用
- Abdelhak A, Benkert P, Schaedelin S, et al. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. JAMA Neurol. 2023. PMID: 37930670. doi:10.1001/jamaneurol.2023.3997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。